熱門資訊> 正文
Coherus Oncology定价股票发行以筹集5010万美元
2026-02-13 16:02
- Coherus Oncology (CHRS) has priced an underwritten public offering of 28.6M shares at $1.75 per share.
- The company expects to raise about $50.1M in gross proceeds before fees and expenses. Coherus is also giving underwriters a 30-day option to buy up to an additional 4.29M shares at the same price.
- The offering is expected to close around February 17, 2026, subject to standard closing conditions.
- The company plans to use the net proceeds to support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its pipeline, and fund working capital and other general corporate purposes.
More on Coherus BioSciences
- Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
- Coherus Oncology announces proposed public offering of common stock
- Coherus, J&J agree to evaluate combination prostate cancer treatment
- Seeking Alpha’s Quant Rating on Coherus BioSciences
推薦文章
美股機會日報 | 特朗普再放豪言！正與伊朗談判，並收到伊方「大禮」；特斯拉機器人再迎新進展！馬斯克稱有望明年實現量產
一圖看懂 | 單季盈利承壓！拼多多Q4營收1239億元同比增12%，調后淨利卻下跌12%；高管稱「力爭三年再造一個拼多多」
財報前瞻 | 美團Q4財報將放榜！大摩、高盛逆勢力挺股價，當前美團已嚴重超跌？
中東戰火中金價狂瀉11%！創43年最慘周跌，避險邏輯崩塌還是黃金坑？
美股機會日報 | 中東硝煙將散？以官員稱美方4月9日結束對伊戰爭！海力士擬籌資百億赴美上市，豪擲80億美元鎖定阿斯麥光刻機！
一圖看懂 | 連續5個季度破千億！小米Q4營收1169億創歷史新高；淨利大增43.8%至63億元
無論美伊談判真假！華爾街已從特朗普引發的五分鍾狂飆獲得明確信號？
麥格理：緊張局勢緩和后布倫特原油底部在每桶85至90美元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
